Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -25.09% is 69% above its 4-year average of -82.02%, near the high end of its 4-year range (-439.77%–-4.98%).
7.24% below its 12-month average of -23.40%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -22.25%.
EBITDA MARGIN
-25.09%
EBITDA MARGIN AVG TTM
-23.40%
EBITDA MARGIN AVG 3Y
-63.69%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-7.24%
CURRENT VS 3Y AVG
+60.61%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Axsome Therapeutics, Inc.
Market Cap
$9.11B
EBITDA Margin
-25.09%
TTM Avg
-23.40%
3Y Avg
-63.69%
5Y Avg
N/A
Market Cap
$9.35B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
Market Cap
$8.78B
EBITDA Margin
14.74%
TTM Avg
-8194.33%
3Y Avg
-4134.44%
5Y Avg
-2789.78%
Market Cap
$8.59B
EBITDA Margin
8.34%
TTM Avg
-21.08%
3Y Avg
-58.51%
5Y Avg
-29.82%
Market Cap
$9.72B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
Market Cap
$8.41B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$10.07B
EBITDA Margin
19.75%
TTM Avg
19.29%
3Y Avg
19.87%
5Y Avg
21.06%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $9.11B | -25.09% | -23.40% | -63.69% | N/A |
| Bruker Corporation (BRKRP)vs › | $9.35B | 13.28% | 13.13% | 16.37% | 17.13% |
| Insulet Corp. (PODD)vs › | $9.39B | 21.67% | 20.24% | 16.36% | 15.66% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.78B | 14.74% | -8194.33% | -4134.44% | -2789.78% |
| Henry Schein, Inc. (HSIC)vs › | $9.60B | 8.11% | 8.11% | 8.28% | 8.19% |
| Caris Life Sciences, Inc. (CAI)vs › | $8.59B | 8.34% | -21.08% | -58.51% | -29.82% |
| Bruker Corporation (BRKR)vs › | $9.72B | 13.28% | 13.13% | 16.37% | 17.13% |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | -3.14% | -1.08% | -5.02% | -19.32% |
| Align Technology, Inc. (ALGN)vs › | $10.07B | 19.75% | 19.29% | 19.87% | 21.06% |
| The Ensign Group, Inc. (ENSG)vs › | $10.08B | 10.47% | 10.43% | 10.38% | 10.85% |
Gross Margin
93.2%
EBITDA Margin
-25.1%
Operating Margin
-24.3%
Net Margin
-24.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -22.25% |
| 2026-03-31 | -31.95% |
| 2025-12-31 | -13.86% |
| 2025-09-30 | -25.96% |
| 2025-06-30 | -22.97% |
| 2025-03-31 | -45.16% |
| 2024-12-31 | -59.40% |
| 2024-09-30 | -57.81% |
| 2024-06-30 | -87.25% |
| 2024-03-31 | -87.26% |
| 2023-12-31 | -134.96% |
| 2023-09-30 | -104.47% |
| 2023-06-30 | -134.71% |
| 2023-03-31 | -4.98% |
| 2022-12-31 | -237.57% |
| 2022-09-30 | -241.79% |
| 2022-06-30 | -439.77% |
